- Samsung (KS:) Organic Products has ADC offer services in a new dedicated facility
- Extensive collaboration reflects successful partnership and expertise
INCHEON,
Samsung Organic products will support a series of ADCs from LigaChem Biosciences programs to Samsung organic products new dedicated ADC installation. The two companies are already collaborating on ADC programs for the treatment of solid tumors. LigaChem Biosciences is a pioneering biotechnology company in the research and development of ADC candidates.
“The latest collaboration will further strengthen Samsung organic products capabilities at all stages of ADC development and manufacturing, as part of our commitment to providing patients with safe, high-quality therapeutic products,” said
“This collaboration with Samsung organic products will be an important step towards strengthening the supply chain of high-quality ADC drugs and improving the competitiveness of both companies in the global ADC market,” said
Samsung organic products The ADC facility is a separate suite, equipped with a 500 liter reactor, supporting the development and manufacturing of ADC therapies. Leveraging the company’s expertise in large-scale antibody manufacturing and process engineering, Samsung organic products ADC service scope extends from late discovery to development and conjugationon.
Samsung organic products has also made active investments through the Samsung life (KS:) Scientific fund in biotechnology companies pioneering ADC binding technologies, toolkit and protein engineering.
For more information, visit:
About Samsung Biologics Co., Ltd.
Samsung organic products (KRX: 207940.KS) is a fully integrated end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish, as well as support in laboratory testing for the biopharmaceutical products we manufacture. Our state-of-the-art facilities are GMP compliant and feature bioreactors ranging from small to large scale to meet different customer needs. Maximize operational efficiency and expand our capabilities in response to the growing demand for biomanufacturing, Samsung organic products offers a total combined capacity of 604 kL at Bio Campus I. The company launched Bio Campus II with the construction of Plant 5, which will be operational in April 2025, adding a biomanufacturing capacity of 180 kL. Additionally, Samsung Biologics America allows the company to work closer to U.S.-based customers.
About LigaChem Biosciences
LigaChem Biosciences, Inc. (LCB) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative drugs by leveraging medicinal chemistry expertise to make conventional biologics more targeted and potent to benefit patients with diseases including medical needs are very unmet. LCB advances sustainable pipelines in the therapeutic areas of antibiotics, antifibrotics, oncology and ADC platform technology. For more information, visit
Contact Samsung Biologics
cair.kim@samsung.com
Contact LigaChem Biosciences
jdy@ligachembio.com
